CLINICAL TRIALS PROFILE FOR FONDAPARINUX SODIUM
✉ Email this page to a colleague
All Clinical Trials for FONDAPARINUX SODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00038961 ↗ | A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased | Completed | Sanofi | Phase 3 | 2001-11-01 | This is a multicentre, randomized, double-blind, placebo controlled study. During this study all the patients will receive background venous thromboembolism (VTE) mechanical prophylaxis with intermittent pneumatic compression (IPC). |
| NCT00038961 ↗ | A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased | Completed | GlaxoSmithKline | Phase 3 | 2001-11-01 | This is a multicentre, randomized, double-blind, placebo controlled study. During this study all the patients will receive background venous thromboembolism (VTE) mechanical prophylaxis with intermittent pneumatic compression (IPC). |
| NCT00060554 ↗ | A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN) | Withdrawn | Schering-Plough | Phase 2 | 2003-04-01 | The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting. |
| NCT00256100 ↗ | Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure. | Terminated | Melbourne Health | N/A | 2004-06-01 | The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure. |
| NCT00320398 ↗ | Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium) | Completed | GlaxoSmithKline | Phase 3 | 2006-01-30 | This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement). |
| NCT00320424 ↗ | Hip Fracture Study of GSK576428 (Fondaparinux Sodium) | Completed | GlaxoSmithKline | Phase 3 | 2006-02-16 | This study is requested by PMDA to confirm the efficacy and the safety for HFS. |
| NCT00333021 ↗ | Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients | Completed | GlaxoSmithKline | Phase 3 | 2006-05-01 | This study is phase 3 study for prevention of VTE in patients with abdominal surgery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FONDAPARINUX SODIUM
Condition Name
Clinical Trial Locations for FONDAPARINUX SODIUM
Trials by Country
Clinical Trial Progress for FONDAPARINUX SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for FONDAPARINUX SODIUM
Sponsor Name
